Get the Stockscreener App
0.5246
2.85%
-0.0154
Sutro Biopharma Inc stock is traded at $0.5246, with a volume of 1.34M.
It is down -2.85% in the last 24 hours and down -43.74% over the past month.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
See More
Previous Close:
$0.54
Open:
$0.54
24h Volume:
1.34M
Relative Volume:
0.96
Market Cap:
$50.01M
Revenue:
$153.73M
Net Income/Loss:
$-106.79M
P/E Ratio:
-0.2947
EPS:
-1.78
Net Cash Flow:
$-115.93M
1W Performance:
-8.29%
1M Performance:
-43.74%
6M Performance:
-85.86%
1Y Performance:
-86.19%
1-Day Range:
$0.5231
$0.5699
1-Week Range:
$0.5231
$0.644
52-Week Range:
$0.5231
$5.17
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma Inc
Sector
Industry
Phone
650-392-8412
Address
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
0.5246 | 50.01M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Downgrade | Wedbush | Outperform → Neutral |
| May-08-24 | Initiated | BofA Securities | Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-06-23 | Initiated | Oppenheimer | Outperform |
| Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jun-18-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Jul-16-20 | Initiated | Wells Fargo | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Oct-07-19 | Initiated | BTIG Research | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Apr-29-19 | Initiated | H.C. Wainwright | Buy |
| Oct-22-18 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
| Oct-22-18 | Initiated | Wedbush | Outperform |
View All
Sutro Biopharma Inc Stock (STRO) Latest News
Benign Growth For Sutro Biopharma, Inc. (NASDAQ:STRO) Underpins Stock's 36% Plummet - simplywall.st
Sutro Biopharma stock hits 52-week low at $0.54 amid market challenges By Investing.com - Investing.com South Africa
Sutro Biopharma stock hits 52-week low at $0.54 amid market challenges - Investing.com Canada
Sutro Biopharma, Inc. (NASDAQ:STRO) Stock Holdings Boosted by American Century Companies Inc. - Defense World
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
Sutro Biopharma announces board member departure By Investing.com - Investing.com Canada
Sutro Biopharma announces board member departure - Investing.com Australia
Sei Investments Co. Takes Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Changing FacesPharma and Biotech HiresMarch 2025 - pharmaphorum
Prudential Financial Inc. Increases Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Thrivent Financial for Lutherans Acquires Shares of 97,096 Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma stock hits 52-week low at $0.58 amid market challenges By Investing.com - Investing.com South Africa
Sutro Biopharma stock hits 52-week low at $0.58 amid market challenges - Investing.com
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of “Hold” from Analysts - Defense World
Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline - Investing.com Australia
Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline By Investing.com - Investing.com South Africa
Connor Clark & Lunn Investment Management Ltd. Sells 110,734 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma lays off dozens of employees in ‘strategic portfolio review’ - MSN
Biotech company based in Peninsula laying off 90% of staff - MSN
HC Wainwright Expects Stronger Earnings for Sutro Biopharma - Defense World
Bay Area biotech company laying off 90% of staff as CEO leaves - San Francisco Chronicle
The Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and more - Medical Marketing and Media
Sutro Biopharma rises after market hours on portfolio review, restructuring - MSN
Sutro Biopharma’s (STRO) “Neutral” Rating Reaffirmed at HC Wainwright - Defense World
Sutro Biopharma stock rating downgraded at H.C. Wainwright - Investing.com Australia
Sutro Biopharma stock rating downgraded at H.C. Wainwright By Investing.com - Investing.com Canada
This Li Auto Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
HC Wainwright Downgrades Sutro Biopharma to Neutral From Buy, Price Target is $2 -March 17, 2025 at 08:33 am EDT - Marketscreener.com
Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform -March 17, 2025 at 07:57 am EDT - Marketscreener.com
Deutsche Bank Adjusts Sutro Biopharma Price Target to $5 From $10, Maintains Buy Rating - Marketscreener.com
Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift By Investing.com - Investing.com South Africa
Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift - Investing.com
Sutro Biopharma (NASDAQ:STRO) Cut to Market Perform at Citizens Jmp - Defense World
Array Technologies, Nextracker, Sutro Biopharma - TradingView
Sutro Biopharma (STRO) Expected to Announce Quarterly Earnings on Monday - Defense World
Sutro Biopharma (NASDAQ:STRO) Cut to Neutral at Wedbush - Defense World
Sutro Biopharma (NASDAQ:STRO) Cut to “Underperform” at Bank of America - Defense World
Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance UK
Sutro Biopharma: Revolutionizing Cancer Treatment with Precision Therapeutics - Apna Kal
Sutro Biopharma Inc Stock (STRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sutro Biopharma Inc Stock (STRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| NEWELL WILLIAM J | CEO |
Mar 05 '25 |
Option Exercise |
0.00 |
18,750 |
0 |
299,239 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 05 '25 |
Option Exercise |
0.00 |
8,750 |
0 |
99,027 |
| ALBINI EDWARD C | CFO AND SECRETARY |
Mar 05 '25 |
Option Exercise |
0.00 |
8,750 |
0 |
135,675 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 04 '25 |
Option Exercise |
0.00 |
9,125 |
0 |
94,025 |
| NEWELL WILLIAM J | CEO |
Mar 04 '25 |
Option Exercise |
0.00 |
31,125 |
0 |
291,625 |
| Chung Jane | PRESIDENT AND COO |
Mar 04 '25 |
Option Exercise |
0.00 |
7,875 |
0 |
100,642 |
| ALBINI EDWARD C | CFO AND SECRETARY |
Mar 01 '25 |
Option Exercise |
0.00 |
25,125 |
0 |
131,868 |
| Chung Jane | PRESIDENT AND COO |
Mar 01 '25 |
Option Exercise |
0.00 |
31,875 |
0 |
102,217 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 01 '25 |
Option Exercise |
0.00 |
20,275 |
0 |
93,227 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 01 '25 |
Option Exercise |
0.00 |
11,250 |
0 |
35,370 |
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):